

R&D Introduction and Strategy



Lee Weng, Ph.D.

President, Mindray Medical USA Corp.

2007 Analyst & Investor Day

Disclaimer


This material contains forward-looking statements with respect to the company's outlook regarding drivers, developments, and trends affecting its worldwide markets, opening of international offices, new product development and commercial launch dates, projected revenues, net income margins, earnings per share, revenue growth targets, net income growth targets, salesforce and distributor targets, projections of the size of China's healthcare market, estimated government expenditures, research and development expenditure targets, the company's manufacturing development plan, and the anticipated results of its product development activities. These statements are based on information available at the time they are made and are subject to a number of risks and uncertainties. Actual results could differ materially from those anticipated by these forward-looking statements as a result of a number of factors, some of which may be beyond the company's control. Factors that affect the Company's business operations and product development, as well as a further list and description of risks and uncertainties associated with Mindray's business, are discussed in its reports filed with the Securities and Exchange Commission, including its most recent annual report on Form 20-F. Mindray disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

- ✓ Offer broad product families for wide market segments worldwide
- ✓ Invest in R&D areas that generate high return
- ✓ Meet customer expectations in target market
- ✓ Move products up the value chain while lowering costs
- ✓ Let innovation drive product advancement


Quality, Performance, Cost-efficiency

R&D Overview

R&D Employee




Investment in R&D



Note: GAAP R&D investment as percentage of sales is 8.8% in 2004, 9.6% in 2005 and 9.4% in 2006

R&D HR Structure



Intellectual Property

Patents


- Issued (in China): 157
- Pending (in China): 223
- Pending (in USA): 69



Mindray R&D Highlights

- ☑ > 1,000 R&D employees
- ☑ Headquarters: Shenzhen; Research centers in Beijing and Seattle
- ☑ R&D pioneer in China on patient monitors, hematology and biochemistry analyzers, and ultrasound imaging systems
- ☑ Introduce 7-9 new products every year since 1999
- ☑ Complete in-house R&D laboratories and testing facilities
- ☑ Large intellectual property portfolio

R&D Organization




Project/Product Prioritization

- ☑ Existing product segments
 - Highly-demanded medical equipments in hospitals or clinics worldwide
 - Well-established technology to reduce R&D risk
 - Good return-on-investment for customers
 - Higher product performance/cost ratio than competitors can offer

- ☑ Expansion to new product segments
 - Broaden the scope of current product offerings
 - Total solution for customers
 - High profit margin on R&D investment

R&D Workflow



Continual Product Improvements

Cost Reduction

- Share common components and materials within and across product platforms and families
- Optimize design and manufacturing process

Continual delivery of value to customers

- Gather additional customer requirements for improvement
- Collect customer feedbacks to help new product introduction
- Upgrade existing product to meet customer demands

Commitment to Quality

- ✓ Product quality is Mindray's lifeline
- ✓ Well established quality system
- ✓ Continual improvement

Quality Standard and Regulation

ISO9001: 2000

ISO13485: 2003

QSR (U.S.A)

MDD、IVDD

CMDR (Canada)

Authoritative Party

CMDC (China)

TUV PS (Germany)

FDA (U.S.A)

Health Canada

2008 New Product Pipeline

New Products in 2008 Pipeline

Product Lines	Products
Patient Monitoring & Life Support Devices	iPM Patient Monitor
	Defibrillator
In-Vitro Diagnostic	2 Models
	23 Chemistry Reagents
Ultrasound Imaging System	2 B/W Model
	3 Color Model
Radiology Imaging System	2 Models

2008 FDA Product Pipeline

8 Models for FDA Clearance in 2008

Product Lines	Products
Patient Monitoring & Life Support Devices	Beneview T5, T8
	PM-7000 Patient Monitor
	PM-60
In-Vitro Diagnostic	BS-200 Chemistry Analyzer
Ultrasound Imaging System	M5 Portable Color Ultrasound
	DC-3 Color Ultrasound
	DC-7 Color Ultrasound
	DP-6800 Portable B/W Ultrasound

Mindray's R&D Advantages

- High-quality and low-cost R&D labor pool. Low material and facility cost.
- Experienced R&D domain experts in USA and China
- Matured R&D organization for quick product development and customer response
- Strong skills in product cost reduction
- Efficiency in clinical trials in China

Strategy and Priorities in 2008

- Establish dedicated marketing teams to gather product requirements for domestic and international markets
- Invest in the US R&D Center to lead technology advancement and product improvement
- Establish a software research center to support product development
- Plan for the Nanjing R&D center to attract local talents
- Seek M&A opportunities to broaden product offering
- Build large patent portfolios and strong IP positions



R&D Introduction and Strategy

Thank You!

Q&A